Multiple Sclerosis. Everything you need to know

But what about the fact that Avonex actually showed lower real-world efficacy because of its slashed dosage and weekly schedule? The drop in performance was real: the trials proved Avonex lowered relapses by only 18%, compared to Betaseron’s 31%. To spin the launch of a less effective drug to the public, the marketing departments simply deployed a single, devastating counter-punch: "Betaseron had zero proven impact on long-term disability, but Avonex slows it down by 37%." I can easily visualize the Biogen executives trying to smother their laughter in corporate boardrooms. Meanwhile, the team at Schering/Bayer must have been utterly sick to their stomachs when they realized how badly they had botched their own data mapping by failing to lock down a disability endpoint. That single mistake evaporated billions of dollars.

The most incredible part of this narrative? Nobody in the medical community seemed bothered by the logical contradiction: a heavy dose of Betaseron (250 mcg every other day) reduces relapses by 31% but fails to alter disability, while a tiny dose of Avonex (30 mcg once a week) reduces relapses by just 18% but magically slows disability by 37%. Let's look at the weekly math: an Avonex patient takes 30 mcg a week, while a Betaseron patient takes 875 mcg a week—a nearly 30-fold difference in active compound. It brings to mind the old idiom about trying to pass off rain as a divine blessing.

I couldn't find exact global registries for the total MS population in 1996, but the corporate press releases from Biogen and Teva during that era continue to quote the exact same static estimate from 1993: 250,000 patients in the US. It was right around this window that MRI scanners began their rapid, systemic rollout across municipal hospitals. By 2001, the first version of the McDonald criteria was officially adopted, anchoring the MRI as the absolute center of MS diagnostics. Almost instantly, the official patient counts in the United States began a steep, relentless climb.

Subcutaneous Interferons Beta-1a

Patients demanded a slowdown in their disability progression, and now interferons were more than ready to give it to them. In reality, the only limits on these numbers were set by common sense. Pushing a trial design to show a 50% disability slowdown wouldn’t have been that difficult given the elastic nature of the EDSS scale, but doing so would have drawn a dangerous amount of scientific scrutiny to the drugs. By the way, I suspect the relatively high figure of 37% chosen by Biogen was a calculated tactical move. If the manufacturers of Betaseron had been a bit bolder and "proven" a 60% relapse reduction, everyone else in the market would have had far more breathing room to manipulate their own data.

The next titan to step onto the interferon battlefield was Rebif. The molecule was engineered by the Swiss biotech firm Serono in 1998, and it almost instantly sailed through European regulatory approval. However, its launch in the United States got bogged down for years—not because of the FDA, but due to vicious patent litigation between the pharmaceutical giants. Serono wanted to patent their specific manufacturing tech and proprietary formulation of interferon-beta-1a, which was tricky considering Biogen’s near-identical Avonex was already selling out worldwide. Still, Rebif brought one key operational upgrade to the table: it was injected subcutaneously (under the skin) rather than deep into the muscle.

Serono’s legal and marketing teams took a far more aggressive track than their rivals. They set out not just to capture a slice of the market, but to lock down exclusive rights to the underlying tech and freeze out future competitors. They claimed that their signature bio-reactor setup yielded a completely peerless molecule—an interferon so uniquely potent that contrasting it with existing brands was structurally incorrect. Furthermore, they asserted that the scientists at Biogen were dead wrong or had actively misled the medical community: to actually change the course of multiple sclerosis, you had to inject interferon beta-1a three times a week, and it had to go under the skin. Never mind that the molecule was supposed to be highly stable in the human body. Sure, the patient would have to endure a non-stop, three-fold increase in fevers and skin reactions, but we are talking about modifying an incurable disease here! This wasn't the place for soft compromises or comfort.

The US chewing gum market in the 1970s and 1980s was saturated to absolute capacity. Five massive conglomerates led by Wrigley had hit a wall where scaling sales volume was physically impossible: gum was already sold at every cash register, and everyone who wanted to chew was already chewing. Wrigley’s marketing strategists solved this market saturation with a stroke of genius: they decided to force existing consumers to double their consumption. They launched a wave of hypnotic TV commercials showing people experiencing pure bliss by tossing two pieces of gum into their mouths at once. The ad copy hammered home the message: Double your pleasure, double your fun, double your mint. I think you know the results of that campaign just as well as I do.

Let's look at the financial math behind Rebif:

The drug rolled off the line in two distinct strengths—22 mcg and 44 mcg. Bizarrely, both tracks required three injections a week. The 22 mcg was the baseline, but patients whose bodies tolerated the side effects were urged to double the dose to unlock "maximum efficacy." How this double-up shifted the biological baseline was never clearly mapped out, but a single 22 mcg shot in the 2010s cost about $300, while the 44 mcg version retailed for $400. It looks a lot like the pricing strategy for a small versus a large cappuccino, doesn't it?

At launch, a year of Rebif therapy was priced roughly 1.5 times higher than both Betaseron and Avonex.

The clinical trials claimed Rebif cut relapses by 29–32% and slowed disability by 23–31%. Remember, Avonex claimed an 18% relapse drop and a 37% disability slowdown. Don't ask me how this mathematical contradiction is biologically possible—nobody knows.

By 2003, Rebif sales shattered the $800 million mark, accounting for a massive 44.1% of Serono’s total corporate revenue.

In 2013, global Rebif sales soared to roughly $2.5 billion, locking it in as the third best-selling multiple sclerosis drug on Earth.

Cumulatively, Rebif has drained global healthcare budgets to the tune of $24 billion.

Do you think the market hit equilibrium there? Not even close. This entire pharmaceutical crossfire unfolded right at the dawn of mass MS diagnostics via MRI. Rebif unlocked its US registration in 2002, and over the subsequent three years, the estimated number of diagnosed patients in the United States exploded from 250,000 to 400,000. This spike was driven entirely by the systemic rollout of tomographs and the arrival of the 2001 McDonald criteria. Pharmaceutical companies launched a highly aggressive medical campaign branded as the "Window of Opportunity." Sales reps bombarded neurologists with the message that every single day a patient spends without therapy results in the irreversible burning away of their brain tissue. Doctors were urged to abandon years of clinical observation and slap on a diagnosis at the absolute first hint of trouble. Happiness for everyone, and let no one leave empty-handed!